TricoPAT®

Introduction to Tricopatting and the Tricopat device

The Tricopat device is an innovative breakthrough, gaining popularity for the treatment and stabilisation of androgenetic alopecia, trichodynia (Scalp hair pain), and other conditions that can cause hair loss and affect the structure and density of scalp hair, in both men and women.

The efficacy of Tricopatting has been scientifically validated by the dermatological team of the University of Bologna in Italy, one of the most prestigious institutions in the field of hair and skin research. Tricopatting is a painless and non-invasive approach to treating a wide range of conditions that result in hair loss.

 

The Tricopat’s Process

Tricopat involves several functions aimed at stimulating hair growth. The two main mechanisms are activation to the anagen (growth) phase of quiescent resting hair follicles, and metabolic cellular activation of the scalp.

• The anagen phase is the active phase of the hair life cycle producing continuous hair growth. By stimulating hair follicles to enter this phase, Tricopat promotes the regrowth of new hair.
• Scalp cell metabolic activation involves optimizing the scalp to promote hair growth. This includes increasing blood circulation, which provides hair follicles with nutrients needed for hair growth, and balancing scalp pH, which can affect hair health.

The aim is not only new hair regrowth, but also hair loss is stopped, and the texture, thickness, and shine of the existing hair shaft is increased.

 

The Skin patting Technique

Tricopat uses a patented technique called Skin patting. This involves a series of dynamic-restructuring actions that, acting synergistically, stimulate hair follicle activity.

Skin patting includes several procedures, including

1. Controlled micro dermo incisions, which creates microscopic openings in the scalp to facilitate the passage of growth factors into the dermis and activates blood supply and regenerative processes in the dermis.
2. Similarly, pressure wave stimulation, like massage, facilitates penetration of active ingredients, stimulates blood supply and tissue oxygenation.
3. Iontophoresis is used to draw the active ingredients through the epidermis, functioning as a kind of needle-free injection.
4. Electrostimulation, on the other hand, elicits muscle contraction by causing an alternating tensing and relaxing action on the scalp, which is also useful in promoting blood flow and opening the pores of the skin to allow the active ingredients to pass through.
5. Finally, photo stimulation using LED light induces a bioenergetic action of stimulating the metabolic activities of skin cells and hair follicles. This combination of all the above techniques makes the Tricopat a unique device.

 

The Treatment Protocol

We recommend a course of 4 to 6 in-clinic sessions, depending on the degree of hair thinning, to be implemented every 4 weeks. Each session lasts about 30 minutes and is absolutely painless because it is injection-free. Most patients even consider it almost pleasantly comfortable.

 

Scientific Findings

The dermatologists at the University of Bologna have done studies on male and female patients with androgenetic alopecia and documented follow-up after 4 and 6 months after treatment with Tricopat technology. They found a significant improvement in hair in all patients characterized by increased hair number and hair shaft diameter.

These results demonstrate the effectiveness of Tricopat in the treatment of androgenetic alopecia, one of the most common causes of hair loss in both men and women.

 

Conclusion

Tricopatting has proven to be an effective technique in treating and preventing androgenetic alopecia. It does so by offering a painless and non-invasive solution for those suffering from hair and scalp problems.

It has proven to be a viable alternative to the more invasive and painful injectable processes like PRP. Its combination of innovative techniques, painless and non-invasive approach, and scientifically proven results make it a very promising treatment option.